TOP TEN perturbations for 1213_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1213_at
Selected probe(set): 203181_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1213_at (203181_x_at) across 6673 perturbations tested by GENEVESTIGATOR:

DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)

Relative Expression (log2-ratio):2.756731
Number of Samples:5 / 17
Experimental DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they died from unknown reasons.
Control DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they died from unknown reasons.

DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; alive)

Relative Expression (log2-ratio):2.5102892
Number of Samples:28 / 14
Experimental DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; alive)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they were alive.
Control DLBCL study 4 (unclassified DLBCL; baseline; CHOP; alive)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they were alive.

DLBCL study 4 (ABC DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (ABC DLBCL; baseline; CHOP; alive)

Relative Expression (log2-ratio):2.4854097
Number of Samples:54 / 19
Experimental DLBCL study 4 (ABC DLBCL; baseline; RCHOP; alive)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they were alive.
Control DLBCL study 4 (ABC DLBCL; baseline; CHOP; alive)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they were alive.

DLBCL study 4 (GCB DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (GCB DLBCL; baseline; CHOP; alive)

Relative Expression (log2-ratio):2.4377136
Number of Samples:91 / 43
Experimental DLBCL study 4 (GCB DLBCL; baseline; RCHOP; alive)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they were alive.
Control DLBCL study 4 (GCB DLBCL; baseline; CHOP; alive)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they were alive.

DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead)

Relative Expression (log2-ratio):2.3779821
Number of Samples:16 / 33
Experimental DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons.
Control DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons.

DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead) / DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead)

Relative Expression (log2-ratio):-2.3190956
Number of Samples:55 / 39
Experimental DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons.
Control DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.087205
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):-2.0608673
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.0425215
Number of Samples:3 / 3
Experimental glioma study 17 (astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)

Relative Expression (log2-ratio):1.9967775
Number of Samples:2 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted).